Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study of Cobitolimod for the treatment of ulcerative colitis: Induction study 2

Next Previous
X
Search
Trial Profile

A phase III study of Cobitolimod for the treatment of ulcerative colitis: Induction study 2

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobitolimod (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Flerie

    • Most Recent Events

    • 27 Feb 2023 According to an InDex Pharmaceutical media release, the company will attend the annual congress of the European Crohn's and Colitis Organisation (ECCO) to provide information about cobitolimod and the ongoing phase III program CONCLUDE. InDex's team member will take the opportunity to meet Investigators of Induction 1 study of the CONCLUDE program to discuss study progress with the coordinating Investigator Professor Raja Atreya.
    • 16 Aug 2022 According to an InDex Pharmaceuticals media release, the PMDA stated overall acceptance for the non-clinical package as well as the study design of the phase III program. Pharmacokinetic data for cobitolimod in Japanese patients will have to be collected prior to applying for market approval, but can be conducted during the remaining phase III program.
    • 16 Aug 2022 According to an InDex Pharmaceuticals media release, the company has received positive feedback from the Japanese regulatory authority, the Pharmaceuticals and Medical Devices Agency (PMDA), regarding the clinical development plan for a future marketing authorization application for cobitolimod. The PMDA has accepted enrolment of Japanese ulcerative colitis patients in this trial, without performing specific Japanese studies prior to study start.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top